- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE Supporting Same-Day Discharge appeared first on Fate Therapeutics.
The post Off-the-Shelf Dual-CAR T-Cell Therapy: Targeting B and T Cells in Autoimmune Disease Without Preconditioning appeared first on Fate Therapeutics.
The post Emerging Data with FT819: Favorable Tolerability and Clinical Activity in Systemic Sclerosis Using Off-the-Shelf, iPSC-Derived Anti-CD19 CAR T cells without Fludarabine appeared first on Fate Therapeutics.
The post Wallace Rheumatic Center appeared first on Fate Therapeutics.
The post University of Louisville appeared first on Fate Therapeutics.
The post Nicklaus Children’s Hospital appeared first on Fate Therapeutics.
The post University of Florida appeared first on Fate Therapeutics.
The post FT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseases appeared first on Fate Therapeutics.
The post Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge appeared first on Fate Therapeutics.
The post Preliminary Phase 1 Results of a MICA/B-targeted CAR T cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy appeared first on Fate Therapeutics.